The Diben® Range

Diabetes-specific nutritional support for patients with or at risk of malnutrition

The Diben® Range

Tailored to Patients’ Metabolic Needs

Help meet your patients’ nutritional energy requirements, without compromising on glycaemic control.

Supports Glycaemic Control

Low glycaemic index (GI) category and modified carbohydrate profile with slow-release carbohydrates and fibre help minimise blood glucose fluctuations.^1-3

High Energy and High Protein

High in energy and protein to support nutritional intake in patients with increased needs or limited intake.

Tailored Fat Profile

High in monounsaturated fatty acids (MUFAs) to support diabetes-specific nutritional management (blood lipids, glycaemic control and insulin sensitivity)^4,5 and selected formats with fish oil.

Is Diben Right for Your Patients?

With approximately 1 in 5 hospitalised elderly adults with diabetes experiencing malnutrition⁵, it’s of the utmost importance to design care plans that meet patients’ energy and protein needs.

Offering diabetes-specific nutritional support, the Diben* range may help your patients:

• Minimise blood glucose fluctuations^1,5• Improve HbA1c levels^1,5• Achieve a more favourable blood lipid profile⁵• Improve insulin sensitivity⁵

Fresubin explains that 1 in 5 diabetic patients experience malnutrition.

Addressing the Two-Fold Challenges of Diabetes

In patients with diabetes or impaired glucose metabolism, nutritional care needs to consider more than blood glucose levels alone. While glycaemic fluctuations are often the highest concern, malnutrition can also be a danger, even in patients who are overweight.^5,6

The Diben range is designed to help address energy and protein needs while supporting glycaemic control.

A woman enjoys Fresubin's Vanilla-flavoured Diben Drink that offers energy and glycaemic control to those with diabetes.

Products to Suit Every Patient

Diben offers drinkable, spoonable, powder and tube feed options to support different nutritional requirements, preferences and feeding routes.

• Diben Drinks and Crèmes: Available in 2 KCAL high-energy, high-protein and standard Drink options with modified carbohydrate profile and fibre.
• Diben POWDER: Diabetes-specific powdered ONS for flexible preparation.
• Diben Tube Feeds: Available in standard and 1,5 KCAL HP options for tube-fed patients under medical supervision.

Fresubin's Diben range is available in a range of flavours and formats, including Diben Drink, Diben 2 KCAL Drink, Diben 1.5 KCAL HP tube feed, Diben POWDER and Diben 2 KCAL CRÈME and Diben CRÈME.

Fresubin® ONS

Discover our wide range of Oral Nutritional Supplements.

Fresubin® Tube Feeds

Explore Fresubin®'s Tube Feed Ranges.

Fresubin Diben factsheets can be downloaded here:

Diben 1.5 KCAL HP Factsheet

Filename: Diben_1.5kcalHP_FS_HCP_Nov2022.pdf
Size: 1 MB
Format: pdf

Diben 2 KCAL CRÈME Factsheet

Filename: Diben_2KCALCreme_FactSheet_HCP_Feb2025_View.pdf
Size: 909 KB
Format: pdf

Diben 2 KCAL Drink Factsheet

Filename: Diben_2KCALDrink_FactSheet_HCP_Feb2025_View.pdf
Size: 830 KB
Format: pdf

Diben CRÈME Factsheet

Filename: Diben_Creme_FS_HCP_Nov22.pdf
Size: 378 KB
Format: pdf

Diben Drink Factsheet

Filename: DibenDrink_FS_HCP_Nov22.pdf
Size: 707 KB
Format: pdf

Diben POWDER Factsheet

Filename: DibenPowder_FS_HCP_Jan2023.pdf
Size: 513 KB
Format: pdf

Diben Factsheet

Filename: Diben_FS_HCP_Nov2022.pdf
Size: 1 MB
Format: pdf

*Diben products are food for special medical purposes, to be used under medical supervision. For the dietary management of patients with/at risk of malnutrition, especially with impaired glucose metabolism such as impaired glucose tolerance, stress-induced hyperglycaemia, diabetes mellitus. For Healthcare Professionals only.

References:

^1.Mayr P et al. Exp Clin Endocrinol Diabetes. 2016;124(7):401-9.
^2.Thomas DE and Elliott EJ. Br J Nutr. 2010;104(6):797-802.
^3. Barazzoni R et al. Clin Nutr. 2017;36(2):355-363.
^4. Quian F et al. Diabetes Care. 2016; 39(8): 1448–1457.
^5. Sanz-París A et al. Clin Nutr. 2020;39(11):3273-3282.
^6. Vural Keskinler et al. Medeni Med J. 2021;36(2):117-122